Top Tweets for #SENSCIS
🖐️ Nailfold capillaroscopy in #SScILD (#SENSCIS substudy)
✅ Over 52 wks, NC metrics were largely stable on nintedanib vs placebo
🔎 Signals in higher-risk groups:
• Risk of rapid FVC decline: capillary density ↓ with placebo, stable with nintedanib
• If ILD progressed: capillary density ↑ with nintedanib, stable with placebo
💡 Suggests a potential microcirculatory effect of nintedanib and supports NC as a candidate tool to monitor progression.
🔓 https://t.co/oC0kUfxxzv
🔥🔥Patients with #ILD due to #SSc or #RA Need Monitoring More Frequently Than Annually
🔍 Methods
▪️Design: Post-hoc analysis of placebo arms in RCTs (SENSCIS and INBUILD).
▪️Population:
#SENSCIS: 288 patients with fibrosing SSc-ILD.
#INBUILD: 47 patients with progressive fibrosing RA-ILD.
▪️Outcome Definition:
ILD progression defined as ≥5% decline in FVC % predicted or death.
▪️Analysis:
Kaplan-Meier estimates for progression over 52 weeks.
Worst observation carried forward for missing data imputation.
✅ Results
🔹SSc-ILD: Progression rates increased incrementally, reaching 36.5% at week 52.
🔹RA-ILD: More rapid progression with 55.3% at week 52.
🔹Kaplan-Meier Curves: Demonstrated time to progression varied significantly between the groups, emphasizing a faster decline in RA-ILD.
💪Strengths:
🔹Clear Question: Addresses a clinically relevant gap in ILD monitoring practices.
🔹Robust Data Source: Utilized RCT placebo arms, minimizing intervention-related bias.
🔹Objective Outcomes: Reliance on standardized decline in FVC % predicted.
⚠️Limitations:
🔹Small Sample (RA-ILD): The INBUILD subgroup (n=47) risks underpowered conclusions.
🔹Post-Hoc Nature: Retrospective analysis limits causal interpretation.
🔹Data Imputation: Worst observation carried forward may overestimate progression.
🔹No External Validation: Findings are restricted to the trial population and lack real-world applicability.
💡 Conclusions
The findings challenge the appropriateness of annual ILD monitoring in autoimmune diseases, suggesting shorter intervals to detect rapid progression, particularly in RA-ILD.
🚩 Implications for Practice
Patients with RA-ILD and SSc-ILD should undergo earlier and more frequent assessments, especially within the first 1-2 years post-diagnosis.
Future research should validate these findings in real-world cohorts and include mortality-specific analyses.
⏩https://t.co/sHdSKnbpEW
@hoffmann_vold describes #SSCILD & wide variation in disease trajectory in the #SLS #SENSCIS #FOCUSSED trials. Hugely important considering generalisability & analysis eligible patients (594/2259) from registry both shocking & unsurprising! More evidence of need 4 @REMAP_ILD
📄 Dyspnée et toux chez les patients avec une pneumopathie interstitielle diffuse associée à la #sclérodermie systémique : données de l’étude #SENSCIS 👤 Résumé par Dr @NihalM_Nice ➡️ À lire sur : https://t.co/vkHPVnyDbN #PID #maladiesrares #FAI2Ralupourvous #fsmr
@KaminskiMed UIP pattern certainly seems to go with antifibrotic response. The thing that stands out for me though is the same benefit for Scl-ILD in #SENSCIS. Whilst ILD is common on SScl, UIP is quite a rare pattern, so I’m not sure it’s ALL about UIP on CT.
Nintedanib for #scleroderma #SENSCIS
➡️Most common adverse event was diarrhoea (75.7%) ➡️Diarrhoea led to permanent treatment discontinuation in 6.9%
48.3% of patients had ≥1 dose reduction and/or treatment interruption https://t.co/LYeqc24rYU
Nuevas terapias antifibróticas en #Esclerodermia
Dr. Alfredo Guillén del Castillo
Estudios #SENSCIS e #INBUILD con #NINTEDANIB muestra menor caída de FVC respecto a placebo. ¿Cambio de práctica clínica en el tratamiento de EPID en EAS? #12GEAS #EAS #SSc #SEMITuit #CTD #EPID
@hayleynbarnes @drdayjee @NEJM @PFFORG @UChicagoPCCM @OrphaLung @slfwalsh @MichiganILD @Lucaric @Boehringer @boehringerus Extrapolating from #SENSCIS study on SSc-ILD (not ideal but that's what we have for now): nintedanib & mycophenolate did not interact, to the contrary there's seems to b an additive effect
#ERS2019 #ERSCongress
Yayyy the first woman on stage!!! 🤩
Dr. Kristin Highland on additional analyses of #SENSCIS trial
Relative decline from baseline stratified by FVC loss > 5%
@Juani1000 talking about SSc-ILD and the recent #SENSCIS trial: some evidence that MMF + nintedanib is better than nintedanib alone (and that has a significant conceptual importance in the management of CTD-ILD) #ARGILD2019
Despite #ATS2019 & #SENSCIS I’m not distracted from my real role in life - #AvocadoToast maker for my youngest daughter. This time with Turkey Bacon, Castelvetrano Olives, over-easy eggs & a lot of love! #MemorialDay2019 #FathersOfDaughters #ChiefsThatCook
@leticiakawano @NEJM @sclerodermaUM @RheumILD @PhilippeDieude @jeffsparks @GarchaMed @KerriBerriKerri @IPFdoc @davidlederer @KaminskiMed In #SENSCIS ,in spite of unprecedented pharmacological slowing of FVC deterioration in #scleroderma using nintedanib, we still haven't affected the QOL of these patients or their symptoms.
#pulmonaryfibrosis #ILD
@bruno_crestani @davidlederer @Juani1000 @pulmonloco @TobyMMaher @GaneshRaghuMD1 @GlassbeMK @OrphaLung @virenkaul @JoshFessel Interesting, from the point of view of mechanism of action, #SENSCIS adds to preclinical data showing that nintendanib acts not only on fibrosis formation but also on inflammation #asExpected
https://t.co/BAABYTkPo7
#SENSCIS Nintedanib In Scleroderma-ILD. Great discussion points led by @leticiakawano. #TwitterJournalClub #ILDTwitter #mustread
1/ Only now I had time to sit and read #SENSCIS results. Sharing some thoughts and I would be happy to hear how the #ILD #Medtwitter community felt about it:
@NEJM @sclerodermaUM @RheumILD @PhilippeDieude @jeffsparks @GarchaMed @KerriBerriKerri @IPFdoc @davidlederer @KaminskiMed
1/ Only now I had time to sit and read #SENSCIS results. Sharing some thoughts and I would be happy to hear how the #ILD #Medtwitter community felt about it:
@NEJM @sclerodermaUM @RheumILD @PhilippeDieude @jeffsparks @GarchaMed @KerriBerriKerri @IPFdoc @davidlederer @KaminskiMed
#HCP: In people living with #SystemicSclerosis #PulmonaryFibrosis may occur. #SENSCIS, presented at #ATS2019, offers new hope.
#PRESS: Phase III #SENSCIS results show investigated compound slows loss of pulmonary function in people living with SSc-ILD #SystemicSclerosis #scleroderma https://t.co/z8tgdyZFUQ
#PRESSE: In Phase III #SENSCIS-Studie untersuchter Wirkstoff verlangsamt Verlust der Lungenfunktion bei systemischer Sklerose mit assoziierter ILD #Sklerodermie https://t.co/Mcv8gJEvlK
4/ Last comment on #SENSCIS that can be generalized 2 any study:
Relative risks don't inform magnitude of tx effect because they depend on the baseline or control tx effect.
For clinical purposes, if you wanna grasp the idea of magnitude of tx effect go absolute: absolute risks!
#PRESS: Phase III #SENSCIS results show investigated compound slows loss of pulmonary function in people living with SSc-ILD #SystemicSclerosis #scleroderma https://t.co/z8tgdyZFUQ
Last Seen Hashtags on Sotwe
beachspotless
Seen from United States
gachansfw
Seen from Chile
omegle() +filter:videos()
Seen from India
dandysworldnsfw
Seen from Canada
pezoneslibres
Seen from Mexico
teeNager
Seen from United States
nijahownsaglock
Seen from United States
omegle or #nolimit() +filter:native_video
Seen from Chile
dhivipotta
Seen from India
น้องเบียร์
Seen from Thailand
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.6M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
89.8M followers
Taylor Swift
@taylorswift13
83.7M followers
Lady Gaga
@ladygaga
75.2M followers
Virat Kohli
@imvkohli
72.9M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
65.9M followers
Bill Gates
@billgates
64.9M followers
Selena Gomez
@selenagomez
62.8M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers